NDX Logo- High Resolution

About Us

NeuroDiagnostics (“NDx”) has the only minimally invasive highly accurate test, DISCERN™, for Alzheimer’s Disease.

Multidisciplinary teams at the NIH and the Rockefeller Neurosciences Institute, led by Dr. Alkon, over the last 30 years led to the development of the three biomarkers. The three biomarkers comprise an AD-Index assay, a Morphometric Imaging assay, and a PKC Epsilon assay.

FDA has granted NDx Breakthrough Status. Our diagnostic biomarkers have been confirmed by autopsy validation (NIH “Gold Standard”).

Resources

Company Overview
Company Overview
Neuro Test
Neuro Test

Team Members

Daniel alkon

Daniel Alkon

Scientific Director

Paul Tanico

Paul Tanico

Executive Chairman

Frank Amato

Frank Amato

President & CEO